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Microhomology-assisted scarless genome editing
in human iPSCs
Shin-Il Kim 1, Tomoko Matsumoto1, Harunobu Kagawa1, Michiko Nakamura1, Ryoko Hirohata1, Ayano Ueno2,
Maki Ohishi2, Tetsushi Sakuma 3, Tomoyoshi Soga2, Takashi Yamamoto3 & Knut Woltjen 1,4
Gene-edited induced pluripotent stem cells (iPSCs) provide relevant isogenic human disease
models in patient-speciﬁc or healthy genetic backgrounds. Towards this end, gene targeting
using antibiotic selection along with engineered point mutations remains a reliable method to
enrich edited cells. Nevertheless, integrated selection markers obstruct scarless transgene-
free gene editing. Here, we present a method for scarless selection marker excision using
engineered microhomology-mediated end joining (MMEJ). By overlapping the homology
arms of standard donor vectors, short tandem microhomologies are generated ﬂanking the
selection marker. Unique CRISPR-Cas9 protospacer sequences nested between the selection
marker and engineered microhomologies are cleaved after gene targeting, engaging MMEJ
and scarless excision. Moreover, when point mutations are positioned unilaterally within
engineered microhomologies, both mutant and normal isogenic clones are derived simulta-
neously. The utility and ﬁdelity of our method is demonstrated in human iPSCs by editing the
X-linked HPRT1 locus and biallelic modiﬁcation of the autosomal APRT locus, eliciting disease-
relevant metabolic phenotypes.
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Functional genomics relies on gene targeting to create orrevert mutations implicated in regulating protein activity orgene expression. This methodology has advanced greatly
across species through the development of designer nucleases
such as ZFNs, TALENs, and CRISPR-Cas91,2, with CRISPR-Cas9
taking the lead due to the simplicity of programmable sgRNA
cloning, coupled with efﬁcient and reproducible genomic clea-
vage. Despite differences in experimental design and DNA clea-
vage mechanism, all engineered nucleases function by generating
targeted double strand breaks (DSBs) to induce cellular DSB
repair (DSBR) pathways. Error-prone repair via non-homologous
end joining (NHEJ) is typically sufﬁcient for gene disruption,
while homology directed repair (HDR) can be usurped with
custom template DNA that acts as a donor in the repair of tar-
geted double-strand breaks, allowing for more speciﬁc gene edit-
ing. These advances are of particular interest in the ﬁeld of human
genetics for disease modeling, where gene targeting in human
induced pluripotent stem cells (iPSCs) with nucleases enables the
original patient iPSC line to act as an isogenic control3.
Although recent advances in nuclease technology have
respectably improved gene targeting efﬁciencies for human
embryonic stem cells (ESCs) or iPSCs, the deposition of single
nucleotide variations which mimic or correct patient mutations
remains difﬁcult without a robust means for enrichment and
selection, such that positive selection for antibiotic resistance
markers remains a staple in gene targeting4. Moreover, positive
selection provides a method for generating clonal populations
with minimal effort. For genome editing by conventional gene
targeting with positive selection, scarless excision of the antibiotic
selection marker is a critical step, yet remains non-trivial using
current approaches. Methods such as Cre-loxP recombination5,
and more recently excision-prone transposition6 have been
shown to remove selection markers after their utility is expended.
However, these methods are fraught with complications such as
residual recombinase sites7, low excision frequencies, and
potential for re-integration8. Alternative methods to achieve
scarless excision must therefore be sought.
Within the repertoire of endogenous cellular repair pathways,
microhomology-mediated end joining (MMEJ), is an under-
appreciated mechanism for repairing DSBs. MMEJ is a Ku-
independent pathway that employs naturally occurring micro-
homology (µH) of 5–25 bp present on either side of the DSB to
mediate end joining9. The outcome of MMEJ is a reproducible
deletion of intervening sequences while retaining one copy of the
µH. For this reason, MMEJ is normally considered to be muta-
genic, because of an overall loss of genetic information by precise
deletion.
In our current research, we address the need for high-ﬁdelity
excision by recruiting MMEJ. Using standard donor vector design
where a point mutation is juxtaposed with a positive selection
marker, we go on to engineer µH that ﬂank the marker through a
PCR-generated overlap in the left and right homology arms. After
positive selection for gene targeting, we introduce DSBs using
validated and standardized CRISPR-Cas9 protospacers nested
between the selection marker and µH, stimulating the cell to
employ MMEJ for scarless excision, leaving behind only the
designer point mutation at the locus. Moreover, employing
imperfect microhomology, we demonstrate that it is possible to
produce isogenic mutant and control iPSC lines from the same
experiment, addressing a current concern in the ﬁeld over the
effects of nuclease and cell culture manipulations10. We employ
this technique in human iPSCs to edit hypoxanthine phosphor-
ybosyltransferase 1 (HPRT1) and biallelically edit adenosine
phosphoribosyl transferase (APRT), deriving iPSC models and
isogenic controls for HPRTMunich partial enzyme deﬁciency11 and
the common Japanese APRT*J allele12, respectively. Measures of
cellular metabolism establish consistent disease phenotypes
between engineered iPSC clones, as compared to concordant
controls. We expect this technique to have broad applications,
even beyond scarless iPSC genome editing.
Results
MMEJ bias towards precise repair outcomes. Gene disruption
using programmed endonucleases relies on cellular error-prone
repair pathways such as NHEJ to produce out-of-frame insertion
and deletion (indel) mutations. We previously exploited this
phenomenon to disrupt HPRT enzyme function in 201B7 human
female iPSCs in order to assess the activities of modiﬁed TALEN
architectures13. In that assay, transient transfection of TALENs
modeled after HPRT1_B14 which target exon 3 of the human
HPRT1 gene (Fig. 1a), followed by metabolic enrichment for
HPRT loss-of-function by 6-thioguanine resistance (6-TGR;
Supplementary Fig. 1) revealed a recurring mutation comprised
of 17 deleted bases (Δ17). TALEN-mediated disruption of
HPRT1 in another female iPSC line (409B2) reproduced the Δ17
allele at a frequency of ~12% (Supplementary Fig. 2). DSBR
outcomes may be biased by short direct sequence repeats towards
alternative MMEJ repair9. We therefore used a modiﬁed script15
to detect µH at the expected DSB site and identiﬁed a 5 bp µH
(µ5: ‘GACTG’) lying within the left TALEN (TALEN-L) binding
site and the intervening spacer region, separated by heterologous
sequence (Fig. 1a). Further examination revealed a shorter µH of
3 bp (µ3: ‘AGA’) adjacent to µ5, separated by only one variant
base (T or A), resulting in an imperfect compound µH of the
structure ‘GACTGWAGA’, where W = T/A (hereafter referred to
as µ5W3). These observations suggested a biased repair pathway
through MMEJ which warranted further investigation.
Considering the HPRT1 locus is X-linked, we set out to explore
the spectrum of DSBR outcomes induced by TALEN in male
1383D6 iPSCs16 and H1 ESCs17. Whilst maintaining the same
target sequences14, HPRT1_B TALENs were updated from a
truncated Xanthomonas oryzae pv. (PthXo1)-based TALE scaf-
fold13 to X. campestris pv. vesicatoria (AvrBs3)-based +136/+63
TALE architecture18 and expressed from a CAG promoter-driven
expression vector. These TALEN vector modiﬁcations resulted in
a 3-fold increase in cleavage activity for AvrHPRT1_B TALENs as
measured by single-strand-annealing (SSA) assay19 (Supplemen-
tary Fig. 3a). Enhanced genome cleavage activity was also
demonstrated in 1383D6 male iPSCs by improved HPRT1
knockout as measured by 6-TGR colony formation (Supplemen-
tary Fig. 3b). We estimated allele frequencies in a bulk population
of 6-TGR iPSCs by employing computational sequence trace
decomposition (TIDE) from mixed PCR amplicons20. In the
sequence trace ﬁle, overlapping peaks were observed immediately
following µ5W3, with a preceding T/A overlay at position ‘W’
(Supplementary Fig. 4a-c). Amongst a variety of minor deletion
alleles, Δ17 was found to be signiﬁcantly overrepresented (63.5%,
Supplementary Fig. 4d), strongly supporting MMEJ through
µ5W3. TIDE veriﬁed a similar frequency in male H1 human ESCs
(43.9%, Supplementary Fig. 4e-g). In order to exclude the
possibility that this apparently high rate of MMEJ repair in the
population was an artifact of PCR bias, we isolated 6-TGR iPSC
clones and performed Sanger sequencing of exon 3 (Supplemen-
tary Fig. 5). Clonal analysis revealed deletions as the most
common DSBR outcome (~88%), amongst which the Δ17 allele
comprised the majority (~64%), consistent with the population-
based TIDE analysis. The Δ17 alleles could be further subdivided
according to the imperfection in µ5W3 at a ratio of 5(T):15(A)
(Fig. 1b,c), presumably dictated by more frequent use of the
longer µ5 for repair, and a concordant loss of the intervening
‘TAGA’ sequence. Both Δ17 deletion types produce a -1 frame
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shift which results in three (D98E, F99L, I100L, for HPRTΔ17T) or
four (V97E, D98E, F99L, I100L, for HPRTΔ17A) missense
mutations terminating in a nonsense mutation (fsTer101),
resulting in loss of HPRT function as measured by resistance to
6-TG and sensitivity to HAT (Supplementary Fig. 6), with no
additional effects on clone morphology or growth rate under
normal culture conditions.
Analysis of the TALEN-mediated HPRT1 knockout data led us
to two key conclusions (Fig. 1d): ﬁrst, that common MMEJ events
result in high-ﬁdelity deletion of intervening sequence, and
second, that MMEJ between imperfect µH (µ5W3) leads to
alternate yet predictable allelic outcomes.
Coincident editing of mutants and isogenic controls. Genome
targeting in human iPSCs beneﬁts from antibiotic enrichment, yet
to achieve scarless editing of patient mutations selection markers
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Fig. 1 TALEN disruption of the HPRT1 locus is biased by endogenous microhomology. a Schematic of the human HPRT1 locus with detail for segments of
exon 3 and 4 (orange) including splice junctions, the HPRT1_B NC- or Avr-TALEN target sites (green), and predicted μ5W3 microhomology (blue) with the
mismatched base (A/T) shown in red. Chromosome positions refer to H. sapiens GRCh38. HPRT1 codons are numbered above. 1383D6 iPSC sequence
trace genome is shown below. SD, splice donor; SA, splice acceptor. b Summary of repair outcomes in 6-TGR clones following transfection of 1383D6 iPSCs
with HPRT1_B Avr-TALENs. Individual clone sequences are listed in Supplementary Fig. 5. c Sequence of the two most commonly observed 17 bp deletions.
d Schematic of the molecular repair events leading to either Δ17(A) or Δ17(T) formation by MMEJ. Note that the intervening 17 bp sequence is similarly
excised, despite the ﬁnal outcome (A or T). μH, microhomology (blue)
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HPRT1 disruption by MMEJ (Fig. 1d), we reasoned that by
engineering duplicated µH from unique endogenous sequences,
such that they ﬂank the antibiotic selection marker, we could
induce the cell to employ MMEJ to repair nested DSBs resulting
in scarless excision and locus restoration with only engineered
point mutations remaining (Fig. 2a). To demonstrate this
microhomology-assisted excision (MhAX) technique, we chose to
edit bases within exon 3 of HPRT1. As HPRT1 is expressed in
human iPSCs, we employed a puroΔTK (a fusion of puromycin to
truncated thymidine kinase) antibiotic counter-selection marker
as a 2A-peptide linked promoterless gene-trap; an approach
similar to that used for background-free AAVS1 targeting16, but
lacking a splice-acceptor sequence in favor of in-frame insertion
into the HPRT1 open reading frame (Fig. 2b). As well, we
included a constitutively expressed CAG::mCherry reporter gene
with the intent to track both gene targeting and excision steps. In
order to introduce DSBs ﬂanking the selection/reporter cassette,
we chose to employ CRISPR-Cas9 rather than TALEN, exploiting
multiple advantages including: a uniﬁed Cas9 protein and sgRNA
plasmid expression system22 and deﬁned endonuclease break-
points23. In selecting protospacer/sgRNA combinations, we
focused on three sgRNAs targeting the GFP gene of A.victoria,
already shown to have high activity and low toxicity in human
U2OS osteosarcoma cells24. Activity of each GFP sgRNA was
determined using an SSA assay in HEK293T cells (Supplementary
Fig. 7a and b), and an AAVS1-CAG::eGFP disruption assay in
human iPSC (Supplementary Fig. 7c). No overt cytotoxicity was
observed for any of the sgRNAs in either assay. Based on these
data, we selected the eGFP1 protospacer (hereafter referred to as
ps1). Duplicated ps1 protospacers were positioned ﬂanking the
cassette in a divergent orientation such that the PAMs and
upstream cleavage sites were proximal to the engineered µH
(Fig. 2a). High-throughput screening and computational analysis
of sgRNA libraries25 has revealed that a ‘G’ nucleotide positioned
downstream of the PAM is unfavorable for Cas9 activity. We
therefore deﬁned potential µH in the genome such that each
nested ps1 PAM would be ﬂanked by a ‘T’ or an ‘A’ nucleotide
(Supplementary Table 1).
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Fig. 2 Imperfect microhomology simultaneously creates iPSCs with patient mutations and their isogenic controls. a Schematic overview of the MMEJ
method for editing HPRTMunich and control alleles. Left and right homology arms overlap, generating a 13 bp tandem µH (blue) ﬂanking the selection
cassette (red). The patient mutation (c.312C>A, red) is present in one µH (unilateral) or both (bilateral). A silent bilateral point mutation (c.306G> T,
blue) generates an AﬂII site. Complementary ps1 protospacers (black) are nested divergently between the µH and cassette, with sequences and cut site
positions indicated in green above. Gene targeting used AvrHPRT1_B TALENs (yellow bolt). Upon transfection of targeted clones with CRISPR-Cas9 (pX-
ps1), DSBs are generated ﬂanking the cassette, proximal to the engineered µH (green bolts). Repair by MMEJ scarlessly excises the cassette, resulting in
two possible editing outcomes. b Detailed schematic of HPRT1 gene targeting and MMEJ resolution. Exons (gray), overlapping homology arms (HA-L/R,
white), µH (blue), ps1 CRISPR-Cas9 target sites (green), and engineered bases are indicated. 2A-puroΔTK is inserted in-frame with HPRT1 exon3. Black
bars indicate Southern blot probes for the indicated restriction fragments. Genotyping primers are shown in red. c FACS scheme used to enrich mChneg
cassette-excised iPSCs. Sorted populations were plated with or without HAT selection for clonal analysis to determine the frequency and ﬁdelity of repair.
d Southern blot analysis of select excised clones revealing restoration of the HPRT1 locus (HPRT-B probe, top) and removal of the cassette (mCherry probe,
bottom). Parental 1383D6 and intermediate 033-U-45 and 033-B-43 targeted iPSCs are included as controls. Genotypes (S, Silent only; M, Munich and
Silent) are indicated above. “x” indicates one clone with aberrant banding. e Sequencing examples of iPSC clones with Munich and/or Silent mutations
derived from clone 033-U-45 (unilateral). Both types of clones are isolated from the same excision experiment
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Considering our observations for repair of the imperfect µ5W3
at the HPRT1 locus (Fig. 1), we surmised that the duality of
outcomes could be intentionally exploited to produce both
mutant and control iPSC clones from a single experiment. We
chose to focus on re-creating the HPRTMunich partial enzyme
deﬁciency11, originally discovered in a patient presenting with
gout caused by hyperuricemia. The HPRTMunich allele results
from a C-to-A transversion mutation (rs137852485; c.312C>A;
S104R)26 located within exon 3 of HPRT1 neighboring the
AvrHPRT1_B TALEN target site. Through an overlap in HPRT1
homology arms, we created a ﬂanking µH ‘TAAGAGATATTGT’
which contained the Munich c.312C>A mutation centrally (bold
underlined) and an additional Silent c.306G>T mutation at the 5’
end of the µH (underlined) that generated an AﬂII restriction site
exclusively for diagnostic purposes (Fig. 2a and Supplementary
Table 1). In order to recapitulate the imperfect µH phenomenon,
we generated two targeting vectors in which the Munich c.312A
patient mutation was either symmetrical (bilateral), or asymme-
trical (unilateral, such that the downstream homology is
‘TAAGAGCTATTGT’) (Fig. 2a). Bilaterally encoded mutations
were hypothesized to be deposited in 100% of clones, while
unilaterally encoded mutations would be deposited in only a
fraction of clones. Both µH contained the diagnostic AﬂII
c.306G>T mutation.
AvrHPRT1_B TALENs were employed to stimulate gene
targeting in 1383D6 iPSCs. PuroR clones were screened by
Southern blot genotyping, mCherry expression by FACS,
sensitivity to HAT, and resistance to 6-TG (Supplementary
Fig. 8a and 9a,b). Excision was induced by transfection with pX-
ps1, producing mChneg populations at a rate of 1.4 and 1.9% for
033-B-43 (bilateral) and 033-U-45 (unilateral), respectively
(Fig. 2c). mChneg cells were therefore FACS sorted to >98%
purity and replated at clonal density with or without HAT
selective pressure. Under HAT selection 033-B-43 yielded no
clones, suggesting either a failure to repair or a phenotypic effect
of the Munich c.312A mutation (Table 1). On the other hand,
under HAT selective pressure 033-U-45 generated iPSC colonies
which all achieved scarless excision but represented deposition of
the Silent c.306T mutation exclusively (49/49), indicating either a
repair bias or supporting the possibility that HPRTMunich clones
retain sensitivity to HAT.
Scarlessly engineered HPRTMunich alleles were produced in the
absence of HAT selective pressure (Table 1). Southern blotting of
clones (Fig. 2d) provided evidence that the HPRT locus was
reconstituted and that transgenes had not re-inserted into the
genome at any detectable rate. Releasing HAT selective pressure
also revealed clones that repaired via NHEJ (Table 1), many of
which (>40%) represented perfect end-joining comprised of ps1
breakpoints, PAMs, and retention of ﬂanking µH (Supplementary
Fig. 8b). From parental clones with bilateral µH, 4.5% (8/179)
excised scarlessly, and all clones bore both the Silent c.306T and
Munich c.312A mutations. Clones from unilateral µH excised
scarlessly at a rate of 6.8% (14/206). Importantly, 9/14 clones bore
both the Silent and Munich mutations, while the remainder (5/
14) carried only the Silent mutation (Table 1) as veriﬁed by
sequencing (Fig. 2e) and restriction fragment length polymorph-
ism (RFLP) analysis (Supplementary Fig. 8c), indicating that we
could reproduce the stochasticity of MMEJ outcomes by
intentionally engineering imperfect homology.
Finally, we set out to examine the phenotypic consequences of
HPRT editing and assess clonal variation. Under normal iPSC
maintenance conditions, no difference in morphology or growth
rate was noted between normal, mutant, or isogenic control
clones (Supplementary Fig. 9a and b). Within 24 h of HAT
treatment knockout iPSCs were completely eliminated, while
HPRTMunich iPSCs showed delayed growth by cell number and a
profound change in cell morphology (Supplementary Fig. 9b,
bottom), leading to complete cell death by prolonged treatment.
Interestingly, unlike knockout iPSCs, HPRTMunich iPSCs also
retained a delayed sensitivity to 6-TG (20 µM, Supplementary
Fig. 9a). Previously, in vitro assays using HPRTMunich patient cell
lysates indicated abnormal hypoxanthine catalytic activity27
although protein levels were normal11,28. Accordingly, while
HPRT protein was undetectable in Western blot analysis of
knockout iPSC line lysates, HPRTSilent or HPRTMunich clones
revealed normal protein expression levels (Supplementary Fig. 9c).
Pathologically, excess hypoxanthine is converted into uric acid
(Supplementary Fig. 1) which can accumulate in the joints and
tendons causing inﬂammatory arthritis, kidney stones, or urate
nephropathy. Capillary-electrophoresis mass spectrometry (CE-
MS) was used to detect ionic metabolites in spent cell culture
media29,30. While HPRTSilent clones had metabolic proﬁles
resembling 1383D6, HPRTMunich iPSCs accumulated both
hypoxanthine and guanine, but to a lesser extent than Δ17 or
033-U-45 knockouts (Supplementary Fig. 9d). These cell growth
and metabolome data are consistent with a low-level salvage of
guanine and hypoxanthine in HPRTMunich cells which is
insufﬁcient for DNA replication and growth in the absence of
de novo synthesis. As such, we generated a unique iPSC model of
an HPRT1 coding-region variant, using the MhAX technique to
scarlessly and stochastically deposit disease-relevant or control
point mutations.
Parameters affecting MMEJ cassette excision. In order to
explore the effects of increasing µH length on MMEJ efﬁ-
ciencies31, we developed a plasmid-based MMEJ assay analogous
to our cassette design used to generate the HPRTMunich allele. We
ﬂanked a CamR/ccdB positive/negative bacterial selection marker
with ps1 protospacers and inserted it into a luciferase expression
vector with ﬂanking µH of increasing length from 0—50 bp
(Fig. 3a,b). Following transfection into HEK293T cells, a positive
correlation between µH length and luciferase activity was
observed, suggesting an improved rate of MMEJ (Fig. 3b).
Excision from an extrachromosomal plasmid in HEK293T cells
may not accurately reﬂect precise excision from the iPSC genome.
We therefore established a contextually relevant chromosomal
assay at the HPRT locus where cassette excision by MMEJ results



















033-B-43 bilateral HAT 0 n/a n/a n/a n/a n/a n/a
no HAT 179 0 171 (75) 8 4.5 0 8
033-U-45 unilateral HAT 49 0 0 49 100 49 0
no HAT 206 0 192 (84) 14 6.8 5 9
arepair events without any additional base mutations, as predicted to occur via MMEJ
bcalculated as (Scarless excision/Samples analyzed)
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03044-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:939 |DOI: 10.1038/s41467-018-03044-y |www.nature.com/naturecommunications 5
in recovery of HAT resistance, along with the deposition of three
synonymous mutations disrupting µ5A3 (c.303A>G, c.304C>T,
and c.306G>A) (Supplementary Fig. 10 and 11). Using TALEN,
MhAX cassettes ﬂanked by µH of 11 bp ‘TGACTGTAGAT’, or
29 bp ‘TGACTGTAGATTTTATCAGGTTAAAGAGC’, the latter
of which contained the synonymous mutations (underlined,
Supplementary Table 1), and with nested ps1 protospacers were
targeted to HPRT1 exon 3 (Fig. 3c). Excision using µ29 gave rise
to higher numbers of HATR colonies (Fig. 3d) even though
mChneg fractions were similar between the two constructs
(Table 2 and Supplementary Fig. 12a), indicating that Cas9
cleavage and cassette excision rates were not affected by µH
length but rather led to enhanced scarless repair by MMEJ.
Genotyping of HPRT1 alleles from µ11 and µ29 mChneg
populations (without HAT enrichment) revealed a >4-fold
increase in scarless repair and mutation deposition (7.8% vs
~35% avg.), similar to the fold-change observed in the plasmid
assay (Fig. 3b). Thus, increasing the length of µH improves
scarless excision from human iPSC chromosomes.
Evidence from DSBR in yeast32 and mouse ESCs33 suggests
that the presence of long heterology (non-homologous sequence
from the end of DSBs until the start of homology) can negatively
impact MMEJ or HDR repair rates. We tested this parameter by
inverting the ps1 protospacers (ps1-rev), such that their PAMs
were placed proximal to the cassette, leading to a 17 or 18 bp
heterology on either end compared to 6 or 7 bp generated in the
PAM-distal orientation used thus far (Fig. 3e and Supplementary
Table 1). Cassette excision rates (% mChneg) using PAM-distal or
-proximal protospacers were similar (Supplementary Fig. 12b),
indicating that orientation itself does not affect CRISPR-Cas9
cleavage. However, MMEJ repair rates were impeded by
elongated heterology as indicated by a reduction in overall HATR
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Fig. 3 Parameters affecting cassette excision by MMEJ. a Schematic of the plasmid-based MMEJ assay measuring luciferase repair. b Luciferase activity as
a function of increasing ﬂanking μH length. Inset shows luciferase activity with 5 bp μH compared to background (0 bp). Error bars show s.e.m. (n= 3).
c Schematic of the HPRT1 chromosomal assay depicting MhAX cassettes and nested ps1 protospacers with ﬂanking 11 or 29 bp of μH. Synonymous
mutations are shown in red. d HATR colonies arising from targeted clones without or with nuclease (pX-ps1) transfection. One representative clone is
shown for each homology length. e Schematic of HPRT1-targeted μ29 MhAX cassettes with inverted ps1 protospacers. Predicted heterology lengths are
indicated for each DSB. HAT-resistant colonies following excision are representative of three independent experiments. HAT-selected populations from
either protospacer orientation are enriched for MMEJ repair (Supplementary
Fig. 12c)









030-26 11 3.5 6/77 7.8
036-08 29 2.8 17/45 35.6
036-12 29 3.4 29/82 35.4
036-14 29 2.8 16/53 30.2
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right). Based on these results, subsequent MhAX experiments
employed elongated µH and maintained ps1 in a PAM-distal
orientation for reduced heterology.
Biallelic modiﬁcation of the APRT locus. Many disease-causing
mutations show autosomal recessive inheritance. To demonstrate
scarless biallelic modiﬁcation using the MhAX method, we chose
to edit the adenosine phosphorybosyl transferase (APRT) gene,
which produces the enzyme required for the synthesis of ade-
nosine monophosphate (AMP) from adenine (Supplementary
Fig. 1). The APRT*J allele (rs104894507; c.407T>C; M136T)
results in partial enzyme deﬁciency causing a buildup of 2,8-
dihydroxyadenine (2,8-DHA) crystals, often leading to kidney
stone formation or more severely, kidney failure12. Although
APRT*J is prevalent in Japanese patients with urolithiasis (79%),
an in vitro iPSC model remains to be generated. Employing a
gene-trap selection marker and constitutive reporter cassette
ﬂanked by PAM-distal ps1 protospacers, we engineered a ﬂanking
32 bp µH (GTACCACGAACGCTGCCTGTGAGCTGCTGGGC)
in which a synonymous c.402A>T Silent mutation (underlined)
generating a diagnostic Acc65I restriction site was present bilat-
erally, while the c.407T>C APRT*J mutation (bold underlined)
was present unilaterally (Fig. 4a and Supplementary Table 1).
CRISPR-Cas9 sgRNAs overlapping the mutation sites in APRT
exon 5 were screened using T7EI digestion and directly in iPSCs
by APRT gene targeting (Supplementary Fig. 13). APRT sgRNA-2
was selected for superior performance in both assays. In order to
reduce random integration of the donor vector backbone, we
employed negative selection for GFP ﬂuorescence34 (Fig. 4a).
PuroR, mChpos/GFPneg iPSC clones were identiﬁed by micro-
scopy, picked, and genotyped (Fig. 4b,c). Mean mCherry ﬂuor-
escence intensity displayed a bimodal distribution (Fig. 4d),
which was linked to copy number by genotyping heterogously
and homozygously targeted clones.
Three each of hetero- and homozygously targeted clones were
subjected to cassette excision via transfection of pX-ps1. Excision
rates were consistently higher for heterozygous (6.7% avg.) versus
homozygous (3.3% avg) targeted clones (Table 3 and Supple-
mentary Fig. 14), reﬂecting the requirement for one or two copies
of the cassette to be removed from the genome. Excised mChneg
populations were isolated by FACS, from which the spectrum of
alleles was analyzed by Sanger sequencing of genomic PCR
products (Table 3). Expectedly, approximately half of the
sequences detected in excised populations from heterozygous
targeted clones were unmodiﬁed normal alleles. Scarless excision
of the cassette occurred at an average rate of 30% amongst
heterozygous clones. Homozygous targeted clones showed an
a Chr16:APRT pos. 88,807,267–88,811,860 (reverse)
p13.3 p12.3 q11.2 q12.1 q21 q22.1 q23.1p12.1 p11.2
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Fig. 4 Biallelic modiﬁcation of the APRT locus. a Schematic overview of the method for scarless engineering of APRT*J and control alleles. Homology arm
overlap generates a 32 bp tandem µH (blue), with the patient mutation (c.407T> C, red) present unilaterally, and the Silent mutation (c.402A> T, blue)
present bilaterally. A GFP reporter is included in the backbone to exclude cells with random donor integration by FACS. Gene targeting used CRISPR-Cas9
(yellow bolt, Supplementary Fig. 13). The remaining elements are as described in Fig. 2a. b Detailed schematic of APRT gene targeting and MMEJ
resolution. The heterozygous SNP (rs8191489) is shown in orange. Additional labeling is consistent with Fig. 2b. c Southern blot analysis of select APRT
hetero- and homozygously targeted clones using genomic (APRT-5’, top) and transgenic (mCherry, bottom) probes. Parental 1383D6 iPSCs are included as
a control. “x” indicates one clone with aberrant banding. d Histograms of mCherry ﬂuorescence intensities in select APRT targeted clones. Note that the
bimodal distribution is correlated with genotype, and therefore CAG::mCh transgene copy-number. e APRT diploid genotypes of clones. Heterozygous
genotypes were resolved using TIDE. Alleles marked as ‘APRT*J’ were also edited with the Silent mutation. f Southern blot analysis of select excised clones
revealing restoration of the APRT locus (APRT-5’ probe, top) and removal of the cassette (mCherry probe, bottom). Parental 1383D6 and intermediate
targeted iPSCs (from c) are included as controls. Genotypes (S, Silent only; A, APRT*J and Silent) are indicated above
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overall reduced rate of scarless excision (13% avg.), lending to a
relative increase in NHEJ alleles. Co-deposition of the Silent and
APRT*J mutations was more common than Silent alone, possibly
due to the unbalanced nature of the imperfect µH (µ6Y25;
Supplementary Table 1). Thus, unilateral µH was again observed
to stochastically generate both silent and pathogenic allele types.
From populations of mChneg cells, clones were isolated and
genotyped. To ensure the identiﬁcation of both alleles, we
included a neighboring heterozygous SNP (rs8191489, G/C) from
intron 3 within the PCR amplicon (Fig. 4b and Supplementary
Fig. 15a), and employed TIDE analysis to decompose hetero-
zygous repair events. The diploid genotypes of all clonally isolated
iPSCs are summarized in Fig. 4e. Scarless excision rates in the
heterozygously targeted clone 052–2–2 were 31.8% (49/154
clones), similar to that predicted from population analyses
(Table 3). Homozygous clone 052–2–11 gave rise to 5.6% (9/
160 clones) with scarless biallelic modiﬁcation, representing
homozygous and compound heterozygous edited genotypes
(Fig. 4e and Supplementary Fig. 15a). Sequence decomposition
revealed that an additional 18 clones with one NHEJ allele
underwent scarless excision of the other allele (Supplementary
Fig. 16), such that the frequency of clones having at least one
scarlessly edited allele (27/160 clones, or 16.9%) was in agreement
with our initial population analysis.
Monoallelically and biallelically edited iPSC clones were
selected and correct gene editing was further conﬁrmed using
Southern blot (Fig. 4f) and an Acc65I RFLP assay (Supplementary
Fig. 17). We phenotyped edited clones by testing their resistance
to 2,6-diaminopurine (DAP, Supplementary Fig. 1 and 15b), a
toxic purine analog35. Parental 1383D6 and homozygous
APRTSilent/Silent mutants displayed severe drug sensitivity to 10
µg/mL DAP treatment, with nearly complete cell killing within
just 48 h (Supplementary Fig. 15b). Heterozygous targeted or
APRT*J/Silent cells had reduced sensitivity to DAP but were
essentially eliminated within 48 h, while homozygous targeted
and APRT*J/*J cells were completely resistant to DAP treatment.
This data veriﬁes a reproducible change in cellular metabolism
amongst APRT gene-edited iPSCs.
Expedited generation of an isogenic allelic series. With the goal
of expediting the scarless gene editing process in iPSCs, we chose
to exploit the high ﬁdelity of gene-trap targeting with copy-
number dependent transgene expression and ﬂuorescent counter-
selection of random targeting events by FACS (Fig. 5a). APRT
gene targeting was carried out as described above (Fig. 4), how-
ever instead of clonal isolation and screening of targeted inter-
mediates, entire puroR populations were harvested in bulk and
subjected to FACS to isolate mChpos/GFPneg iPSCs (Fig. 5a,b).
We further separated the mChpos population into mChlow (52.9%
of total) and mChhigh (15.5% of total) (Fig. 5b) in order to enrich
for heterozygous or homozygously targeted cells (Fig. 4d),
respectively. Cassette excision was more efﬁcient from the
mChlow than mChhigh (7.0 vs 2.6%) bulk population (Fig. 5b),
consistent with excision one or two transgene copies from het-
erozygous or homozygously targeted clones (Table 3), suggesting
that the MhAX method may be expedited by FACS when the
ﬁdelity of targeting is high.
Genotyping of the two excised populations classiﬁed alleles
into 3 categories: non-targeted, which includes normal alleles or
indel alleles generated by APRT sgRNA-2 during gene targeting;
NHEJ, which arise during repair of cassette excision (distin-
guished from APRT sgRNA-2 indels as they retain engineered µH
and cassette sequences, similar to that shown in Supplementary
Fig. 8b); and MMEJ, which resolve scarlessly and retain the
pathogenic APRT*J and/or Silent mutations (Fig. 5c and Table 4).
Notably, while the mChhigh population was biased toward NHEJ
and MMEJ, the mChlow population contained more frequent
indels (37.5 vs 6.1% for mChhigh), validating FACS enrichment of
monoallelically or biallelically targeted cells, but also reﬂecting the
potential of CRISPR-Cas9 to elicit error-prone repair of DSBs in
opposition to HDR. A similar process of FACS-based targeting
and excision for the X-linked HPRTMunich allele (Supplementary
Fig. 18 and Supplementary Table 2) gave rise to scarless gene
edited clones at a rate comparable to that observed previously for
cloned intermediates (5.6 vs 8%; Table 1) without a signiﬁcant
proportion of normal or indel alleles. Excluding non-targeted
normal and indel alleles from the APRT analysis, the ﬁdelity of
scarless repair of target alleles was estimated to be slightly higher
for the mChlow population compared to mChhigh (26.5 vs 22.7%).
Finally, we performed clonal isolation from bulk excised
populations for the analysis of APRT diploid genotypes (Fig. 5d).
Although TIDE analysis revealed compound heterozygous
genotypes including indel and NHEJ alleles (as seen in Fig. 4e),
we focused only on biallelic editing, or monoallelic editing where
the alternate allele was normal. Monoallelic editing was biased in
clones from mChlow sorting (Fig. 5d, top), while biallelically
edited clones were more prevalent from mChhigh (Fig. 5d,
bottom). Thus, the simultaneous isolation of an allelic series in
iPSC which have been handled under equivalent experimental
conditions provides a new source of monoallelic (APRT*J/Norm
and Silent/Norm) and biallelic (APRT*J/Silent and APRT*J/
APRT*J) isogenic parity (Fig. 5e).
Discussion
Microhomology-mediated end joining reproducibly deletes one
copy of tandem homology along with intervening genomic DNA
sequences to generate deletions of predictable size9,15,31. In the
current study, we report the development of a scarless genome
editing approach termed MhAX (microhomology assisted exci-
sion), where artiﬁcially engineered µH accompanied by nested
CRISPR-Cas9 target sites predisposes DSBR toward scarless
excision of a selectable marker. Demonstrations of monoallelic
and biallelic editing to deposit disease-relevant HPRTMunich or
APRT*J mutations highlight the precision of this endogenous
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052-2-13 Het 5.0 50 30 17 (8) 3 15.0 1 2
052-2-21 Het 6.8 46 24 14 (11) 8 36.4 4 4
052-2-11 Homo 3.4 45 0 40 (26) 5 11.1 0 5
052-2-52 Homo 3.6 53 0 47 (30) 6 11.3 1 5
052-2-61 Homo 2.9 46 0 38 (30) 8 17.4 0 8
aRepair events without any additional base mutations, as predicted to occur via MMEJ
bCalculated as (Scarless excision/Samples analyzed)
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pathway. Based on conventional donor construction and standard
gene targeting principles which have been employed in the ﬁeld
for decades36,37, MhAX provides a tractable methodology which
enhances established gene targeting pipelines. When recruiting
HDR to deposit point mutations, dsDNA donors present an
advantage over ssDNA through extension of the conversion tract
from tens to hundreds of bases from the DSB38. Our approach is
complementary to NHEJ or MMEJ mediated insertion of
transgenic cassettes ﬂanked with minimal homology arms fol-
lowing nuclease cleavage of both the donor and target genome39–
41. Analogous to recombinase-based cassette removal techniques,
yet completely independent of residual exogenous recombinase
sites42, MMEJ-based transgene excision could have similar broad
applications in the precise elimination of foreign genetic elements
for gene or cell therapy applications, and possibly even condi-
tional gene manipulation.
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Fig. 5 Expedited biallelic gene editing by FACS sorting. a Schematic of the FACS sorting protocol. GFPneg / mChpos cells (targeted) are isolated in bulk and
subjected to nuclease transfection, followed by sorting populations for mChneg (excised). Resolved alleles were screened in the population, or in single-cell
derived iPSC clones. The donor vector, allele and additional features are as described in Fig. 4a,b. b Representative FACS plot for the targeting and excision
steps. GFPpos cells were excluded, and mChpos cells were divided into high and low fractions to bias monoallelically and biallelically targeted cells,
respectively. c Predicted APRT allele spectrum within the sorted mChneg populations. d APRT diploid genotypes of clones. Only clones with Normal or
MMEJ-resolved alleles are shown. Alleles marked as ‘APRT*J’ were also edited with the Silent mutation. e By employing imperfect μH, MhAX derives
edited cells and their concordant isogenic controls simultaneously, reducing technical variation
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In this initial demonstration of MhAX, we achieved excision
rates from ~5–35%, which is practical for clonal isolation of iPSCs
with biallelic modiﬁcation. In human iPSCs, we empirically ver-
iﬁed published observations that longer µH improves MMEJ
repair rates43. NHEJ deletions ranging from 0.5–8 kb of the
MALAT1 gene using CRISPR-Cas9 and paired sgRNAs in human
H9 ESCs showed an inverse correlation between deletion size and
efﬁciency44, suggesting that consolidation of selection markers to
reduce cassette size (here ~5 kb) may further improve excision
rates. Additionally, µH characteristics such as GC-content or
reduced distance from the break site (heterology)45,46 may affect
MMEJ. Heterologous tails of 8–9 bp were shown to be less inhi-
bitory to MMEJ in mammalian cells than yeast47, and our data
indicates that heterology >7 bp impedes, but does not completely
prevent MMEJ in human iPSCs. Heterology could be theoretically
reduced to zero by overlapping, rather than abutting, endogenous
and operational sequences. It should be noted that the extent to
which these parameters warrant manipulation may depend upon
the sequence context of the target locus, and that for additional
interrogation of DSBR processes in human iPSCs, our HPRT
reconstitution assay could prove effective.
MhAX uses unique CRISPR-Cas9 protospacers and cognate
sgRNAs for excision (here ps1, targeting eGFP-derived sequen-
ces), which may be further optimized for high activity, low
cytotoxicity, and reduced homology to the host genetic back-
ground, using parameters deﬁned from large scale screens25. A
comparable ssODN-based scarless editing method, which
requires two rounds of targeting to generate point mutations,
demands the design and assay of specialized CRISPR-Cas9
sgRNAs which are limited by the target locus48. Moreover, those
sgRNAs retain high similarity to edited alleles and were shown to
re-cleave them at low frequency. Custom MhAX sgRNAs, on the
other hand, can be freely designed to have consistent cleavage
activity and restricted off-target proﬁles. Moreover, since proto-
spacers employed in MhAX are completely removed from the
genome after excision, both the corrected and mutant alleles are
protected from subsequent cleavage events, allowing the sgRNAs
to be recycled after their initial use. Further improvements in
protospacer prediction49 and CRISPR-Cas9 engineering50 will
continue to aid reagent design.
Gene targeting may be streamlined using ﬂuorescent enrich-
ment for HDR and against random donor plasmid integration34.
In the current work, we combined gene-trap selection with
constitutive expression of CAG::GFP to exclude random inte-
gration, and CAG::mCherry in order to track targeting and
excision in populations, without the need for intermediate clon-
ing. Furthermore, separation of the bimodal mChpos population
ultimately enriched for monoallelically and biallelically edited
iPSCs. In cases where consistent scaling of reporter gene
expression between heterozygous and homozygous targeting may
not be observed, isolation of biallelically modiﬁed iPSC clones
could be achieved using dual-ﬂuorescent, or dual-drug positive
selection16. FACS for mChneg iPSCs, along with PCR and more
conclusive Southern blot genotyping provided evidence that
excised transgenes do not readily re-insert into the genome,
presenting a potential advantage over transposition51,52, which
also requires retention of a proximal transposon footprint.
Genetic background has been implicated in contributing the
greatest source of variation between iPSC lines53,54, such that
debate over what constitutes appropriate controls remains. The
creation of isogenic controls directly from patient or normal
iPSCs constrains genetic backgrounds facilitated by genome
engineering3. However experimental manipulations such as
nuclease exposure, extensive subcloning, and prolonged passage
may additionally contribute to subtle deviations from the original
parental cell line10. Using a plasmid recircularization assay,
mismatched base conversion within MMEJ junctions has been
shown to occur in yeast32, reminiscent of our observations at the
human HPRT1 locus. Our intentional use of imperfect µH to
direct MhAX allowed the isolation of both mutant and normal
isogenic clones from a single experiment. Thus, gene editing
using the MhAX technique combined with unilaterally-
engineered point mutations retains the closest possible relation
between two clonal cell lines, opening a new dimension to the
interdependence of isogenic controls.
Methods
Plasmid construction. Supplementary Table 3 provides a list of sequence-veriﬁed
plasmids used in this study. Primers used for cloning and validation are listed in
Supplementary Tables 4-6. Complete sequences are available through Addgene or
upon request. Detailed cloning histories are available upon request as Snapgene
ﬁles.
HPRT1_B NC-TALENs were described previously13. Avr-TALEN expression
vectors with non-repeat-variable di-residue (non-RVD) variations were assembled
using the Platinum TALEN method18, into a modiﬁed ptCMV-136/63-VR
expression vector containing a CAG promoter instead of CMV. The DNA-binding
modules were then assembled using the two-step Golden Gate method. Assembled
modules were as follows: Left, HD HD NI NG NG HD HD NG NI NG NN NI HD
NG NN NG NI NN NI NG; Right, NI NG NI HD NG HD NI HD NI HD NI NI
NG NI NN HD NG.
For CRISPR-Cas9 expression, sgRNA oligos were annealed and cloned into
pX330 (Addgene plasmid #42230, a gift from Feng Zhang) linearized with BbsI as
previously described22. The resulting plasmids were sequence veriﬁed using primer
dna790.
The HPRT1 SSA reporter vector was used as previously described13. Additional
SSA reporter vectors for AAVS1 TALENs and eGFP sgRNAs were generated by
annealing oligos consisting of the target genomic sequence followed by ligation into
pGL4-SSA linearized with BsaI.
To derive homology for HPRT1 gene editing, a larger region of 1253 bp
surrounding the HPRT1_B TALEN target site was PCR ampliﬁed from 201B7 iPSC
genomic DNA55, cloned into a minimal pBluescript backbone, and sequence
veriﬁed. To derive homology for APRT gene editing, a larger region of 1256 bp was
PCR ampliﬁed from 1383D6 iPSC genomic DNA, cloned using the Zero Blunt
TOPO PCR Cloning Kit for Sequencing (Invitrogen), and sequence veriﬁed. The
resulting plasmid (pCR4-hAPRT-G) represents the rs8191489 G allele.
The puroΔTK selection marker was designed as previously described56, and
constructed in an AAVS1 donor vector (Addgene plasmid #22075, a gift from
Rudolf Jaenisch). A modiﬁed version (KW999) containing the CAG::mCherry
reporter and unique ﬂanking restriction sites was constructed using pAAVS1-P-
CAG-mCh (Addgene plasmid #80492) as a base. The pCAG-eGFP-pA plasmid
(KW991) used as a negative-selection backbone was constructed by Gateway
cloning (Invitrogen) of a pENTR-eGFP Entry vector.
Two different strategies employing one-pot InFusion cloning (Clontech) were
used to generate HPRT1 and APRT donor vectors. For plasmids KW836, KW838,
and KW883 the p3-HPRT1 vector was inverse-PCR ampliﬁed with primers that
included all operational sequences for excision and MMEJ repair, including: the
ps1 protospacer and PAM sequences, appropriately engineered µH, as well as Silent
and Munich mutations, and terminating with 12–15 nt InFusion overhangs. For
KW794, a version of the p3-HPRT1 homology plasmid containing an MC1::DTA
negative selection marker was used as a template. The 2A-puroΔTK selection
marker was ampliﬁed such that the T2A and selection marker coding region were
in-frame with HPRT1 exon 3. All PCR-ampliﬁed regions were veriﬁed by
Table 4 APRT allele spectrum of excised populations following FACS enrichment
Non-targeted NHEJ MMEJ
mCh Pop. Samples analyzed Normal allele Indel NHEJ (perfect) Silent ONLY APRT*J & Silent Fidelity (%)
low 56 1 21 25 (10) 2 7 16.1
high 49 2 3 34 (21) 1 9 20.4
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sequencing. The CAG::mCherry reporter was introduced directly by restriction-
ligation or sequentially through a CAG::Gateway cassette from pAAVS1-P-CAG-
DEST (Addgene plasmid #80490), followed by Gateway cloning of mCherry. For
plasmids KW883, KW1005, KW1033, and KW1034, left and right homology arms
were PCR ampliﬁed to include InFusion homologies, ps1 protospacer and PAM
sequences, and appropriately engineered µH. The plasmid backbone and selection/
reporter cassette were prepared as restriction fragments from KW991 (Acc65I) and
KW999 (BglII +HindIII), respectively. The four fragments were assembled in a
single InFusion cloning reaction, and PCR-ampliﬁed regions were veriﬁed by
sequencing.
MMEJ assay plasmids were constructed by InFusion cloning. The Ampicillin
selection marker was initially swapped for Kanamycin to generate pGL4K. For µH
sizes of 0—30 bp, the ps1 protospacers and PAM sequences were introduced with
the µH by inverse PCR of the pGL4K plasmid, and the CamR/ccdB selection
marker was ampliﬁed with common primers. For µH sizes of 40 and 50 bp, part of
the µH was added to the CamR/ccdB amplicon.
SSA and MMEJ assays. HEK293T cells (Thermo Scientiﬁc) were maintained in
culture medium containing DMEM, 10% FBS, penicillin-streptomycin, and
L-glutamine. SSA assays were carried out as previously described19, and MMEJ
assays followed a similar design. Brieﬂy, DNA mixtures containing 200 ng each of
TALEN or CRISPR-Cas9 nuclease expression vectors, 100 ng of the appropriate
pGL4-SSA (SSA assay) or pGL4K-MMEJ-eGFP1-µX (MMEJ assay) target vector,
and 20 ng pGL4_74_hRlucTK Renilla reference vector (Promega) were prepared in
25 µL of Opti-MEM I reduced-serum medium (Invitrogen) in a 96-well plate.
Twenty ﬁve microliter of Opti-MEM I containing 0.7 µL of Lipofectamine 2000
(Invitrogen) was then added, and incubated at room temperature for 15 min.
HEK293T cells were then added at a density of 4 × 104 cells per 100 µL in culture
medium, and incubated at 37 °C, 5% CO2 for 24 h. To assay luciferase activity,
plates were ﬁrst equilibrated to room temperature before replacing 75 µL of growth
medium with 75 µL of Dual-Glo reagent (Promega). After 10 min incubation, 150
µL of reaction was transferred to a white microtitre plate, and luminescence (1 s)
was read on a Centro LB960 (Berthold) or 2104 EnVision Multilabel Plate Reader
(Perkin Elmer). Following the addition of 75 µL Stop reagent and 10 min incu-
bation, Renilla luminescence was similarly read. Relative luminescence was cal-
culated by the ratio of Fireﬂy/Renilla intensity.
T7EI assay. T7EI assays were performed as previously described57 with some
modiﬁcations. APRT nuclease expression plasmids (1 µg each) and 6 µL FugeneHD
(Promega) were incubated in 150 µL of Opti-MEM I at room temperature for 15
min. HEK293T cells (3 × 105 in 300 µL Opti-MEM I) were incubated with the
transfection complexes at room temperature for 5 min before plating in a 6-well
dish in culture medium. After incubation at 37 °C, 5% CO2 for 96 h, cells were
harvested and genomic DNA was isolated using the DNeasy Blood & Tissue Kit
(Qiagen) according to the manufacturer’s instructions. The APRT locus was
ampliﬁed from 100 ng of genomic DNA by PCR with Phusion Hot Start II High-
Fidelity DNA Polymerase (Thermo Scientiﬁc) using the primers listed in Supple-
mentary Table 7. The resulting PCR products were puriﬁed by Agencourt AMPure
XP (Beckman Coulter) according to the manufacturer’s instructions. 200 ng pur-
iﬁed PCR products were denatured in NEBuffer 2 (New England Biolabs) at 95 °C
for 5 min and re-annealed at a controlled rate of −0.1 °C/s. Samples were divided in
half and 1 µL of T7 Endonuclease I (New England Biolabs) or ddH2O was added
followed by incubation at 37 °C for 15 min. The T7EI reaction was stopped with
0.25M EDTA. Digestion products were analyzed by gel electrophoresis and indel
frequencies were calculated by densitometry in ImageJ (NIH) using the formula:
100 × (1—(1—(b + c) / (a + b + c))1/2).
Human ESC and iPSC culture. Undifferentiated human ESCs and iPSCs were
maintained under feeder-free conditions as described previously58. Brieﬂy, H1
human ESCs17 and 1383D6 human iPSCs16 were cultured on recombinant human
Lamin-511 E8 fragment (iMatrix-511, Nippi) coated 6-well tissue culture dishes
(0.5 μg/cm2) in StemFit AK03 or AK02N (AJINOMOTO) medium. For passaging,
cells were detached by treatment with 300 μL Accumax (Innovative Cell Tech-
nologies, Inc.) at 37 °C for 10 min, followed by gentle mechanical dissociation with
a pipette. To collect the cells, 700 μL of culture medium containing 10 μM ROCK
inhibitor, Y-27632 (Wako) was added. Cells were counted using trypan blue
exclusion on a TC20 (Bio-Rad). Typically, 1–3 × 103 cells per cm2 were seeded on
each passage in media containing Y-27632. After 48 h culture, the medium was
changed without Y-27632. Five to seven days after plating, the cells reached
80–90% conﬂuency and were again prepared for passage. To make frozen stocks,
iPSCs were resuspended at a density of 1 × 106 viable cells per 1 mL STEM-
CELLBANKER (Takara) and 200—500 μL of cell suspension (2–5 × 105 iPSC) was
transferred to a cryogenic tube. Stock vials were defrosted onto iMatrix-511 coated
6-well tissue culture dishes (one vial per 10 cm2) in StemFit AK03 or AK02N
medium containing Y-27632.
Maintenance of 409B2 human iPSCs59 was carried out on SNL feeder cells60 in
Primate ES Cell medium (ReproCELL). For passaging, SNL feeder cells were
detached from the well by incubation with 300 μL CTK solution containing 1 mg/
mL collagenase, 0.25% trypsin, 20% KSR, and 1 mM CaCl2 in Dulbecco’s
phosphate buffered saline (DPBS), Mg2+ and Ca2+ free (Nacalai Tesque) for 2 min
at room temperature. CTK solution was then removed and wells were washed twice
with 2 mL DPBS. 1 mL of Primate ES Cell medium supplemented with
Recombinant Human FGF-basic (PEPROTECH) was added and colonies were
collected with a cell scraper and dissociated into small clumps by pipetting up and
down a few times throughout the entire well. The split ratio was ~1:5 to a fresh SNL
feeder-coated dish.
HPRT disruption with TALENs. HPRT1 knockout experiments using NC-
TALENs in 409B2 iPSCs were carried out on SNL feeders with delivery of DNA by
Neon (Invitrogen) electroporation as previously described13. TALEN evaluation
assays and HPRT1 knockout experiments using Avr-TALEN in H1 ESCs and
1383D6 iPSCs were carried out under feeder-free conditions with delivery of DNA
by NEPA21 (Nepa Gene Co., Ltd) as previously described16. Brieﬂy, CAG-dNC-
HPRT1 TALENs (3 µg each) or CAG-Avr-HPRT TALENs (3 µg each) were
transfected by NEPA21 electroporation into 1 × 106 cells in a single-cell suspen-
sion. Electroporated cells were plated at a density of 1–5 × 105 cells / 60 mm culture
dish. Two days after electroporation, 6-thioguanine (6-TG, 20 µM; Sigma-Aldrich)
selection was initiated, with daily feeding over a period of 7–10 days. For popu-
lation analyses, at cultures of at least 50–300 colonies were pooled for genomic
DNA preparation. For clonal analyses, iPSC colonies were picked in 5-10 µL
AK02N medium using a micropipette and transferred with gentle dissociation into
a 96-well tissue culture plate containing AK02N medium (10 µM Y-27632). Iso-
lated clones were incubated at 37 oC, 5% CO2 for 6-10 days in AK02N medium. At
80-90% conﬂuency, the well was washed with 100 µL DPBS and incubated with 30
µL of Accumax for 20-30 min at 37 oC, 5% CO2. Accumax was removed and
colonies were dissociated with a multichannel micropipette in 100 µL of AK02N
medium containing 10 µM Y-27632. Cell suspensions were split evenly for FACS
analysis, gDNA isolation, or freezing in foil-wrapped 96-well plates in STEM-
CELLBANKER (TaKaRa) at -80 oC previously described58. Selected clones were
defrosted and expanded for permanent storage in liquid nitrogen.
iPSC gene targeting. Gene targeting was carried out essentially as described16.
Brieﬂy, nuclease expression vectors (1 µg each TALEN or Cas9/sgRNA plasmid)
and donor vectors (3 µg) were transfected by NEPA21 electroporation into 1 × 106
cells in single-cell suspension. Electroporated iPSCs were plated at a density of
1–5 × 105 cells per 60 mm culture dish in Stemﬁt media containing Y-27632. Two
days after electroporation, Y-27632 was removed and 0.5 µg/mL puromycin
(Sigma-Aldrich) added, with daily feeding over a period of 7–10 days. Clones were
isolated manually with a micropipette and processed under feeder-free conditions
in 96-well format as described above. For FACS-based MhAX gene editing, puroR
colonies were pooled and passaged once in bulk or directly subjected to FACS.
Genotyping by 5′, 3′ and spanning genomic PCR, junction sequencing, and
Southern blot is described below.
Cassette excision. To initiate cassette excision, 1 or 3 µg of pX-ps1 expression
vector was transfected by NEPA21 electroporation into 1 × 106 cells in single-cell
suspension, and plated at a density of 1–5 × 105 cells per 60 mm culture dish in
Stemﬁt media containing Y-27632. Two days after electroporation, Y-27632 was
removed.
Cassette excision enriched by HAT selection (1 × ) (Sigma-Aldrich or Gibco)
was carried out with daily feeding over a period of 7–10 days. Selection with FIAU
against the ΔTK marker in the 2A-puroΔTK gene-trap cassette was inefﬁcient, and
therefore not used to enrich for excised clones in this study. Enrichment of
cassette-excised mChneg cells by FACS was performed. iPSCs electroporated with
pX-ps1 were plated as usual and allowed to recover in the absence of selective
pressure. After 5 to 7 days, cells were subjected to FACS sorting as described below.
Recovered mChneg cell populations were counted and plated for bulk analysis or at
clonal density (400–800 cells per 60 mm dish) in the absence of HAT (1×). iPSCs
under HAT selection were plated at a 10-fold higher density (4000–8000 cells per
60 mm dish) than unselected in order to obtain similar colony numbers. Clones
were isolated manually and processed under feeder-free conditions in 96-well
format as described above. Genotyping by PCR, sequencing, and Southern blot is
described below.
Flow cytometry and cell sorting. For routine measurement of GFP or mCherry
ﬂuorescence intensities, ~3.0 × 105 cells were suspended in FACS Buffer (DPBS
supplemented with 2% FBS) and analyzed using a BD LSRFortessa Cell Analyzer
(BD Biosciences) with BD FACSDiva software (BD Biosciences). mCherry ﬂuor-
escence intensities of targeted clones were measured in 96-well format on a
MACSQuant VYB (Miltenyi Biotec).
For the isolation of targeted GFPneg / mChpos targeted, or cassette-excised
mChneg iPSCs, cells were harvested as a single-cell suspension in FACS Buffer at a
density of ~1 × 106 cells per mL and ﬁltered through a cell-strainer to remove
clumps. After setting gates for singlets, the desired population was collected on a
BD FACSAria II cell sorter (BD Biosciences) into Stemﬁt AK02N medium
containing 10–20 µM Y-27632. Sorting efﬁciencies were determined using a BD
LSRFortessa Cell Analyzer.
Flow cytometry data were analyzed and generated by FlowJo software v9.7.6 or
higher (Tree Star).
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Genomic DNA isolation. Genomic DNA from populations or clones for PCR
screening and sequencing was extracted from 0.5—1 × 106 cells using a DNeasy
Blood & Tissue Kit (Qiagen) according to the manufacturer’s instructions. Geno-
mic DNA for Southern blotting of clones was extracted from one conﬂuent well of
a 6-well dish (at least 3 × 106 cells) using lysis buffer (100 mM Tris-HCl, pH 8.5, 5
mM EDTA, 0.2% SDS, 200 mM NaCl, and 1 mg/mL Proteinase K), followed by
standard phenol/chloroform extraction, ethanol precipitation, and resuspension in
TE pH 8.0. For high-throughput Southern blotting or PCR screening, genomic
DNA was extracted in 96-well format61 using plate lysis buffer (10 mM Tris-HCl,
pH 7.5, 10 mM EDTA, 0.5% sarcosyl, 10 mM NaCl, and 1 mg/mL Proteinase K)
followed by direct ethanol precipitation and re-suspension in restriction digestion
mix or TE pH 8.0. For clonal analyses from mChlow and mChhigh FACS-sorted
populations, each iPSC colony was manually picked with a micropipette in a 5 µL
volume of media and added to 10 µL of QuickExtract DNA Extraction Solution
(Epicenter). Samples were processed by heating to 65 °C for 6 min then 98 °C for 2
min prior to PCR.
PCR genotyping. Genomic PCR was performed using AmpliTaq 360 (Applied
Biosystems), KAPA HiFi, or KAPA Taq Extra (KAPA Biosystems) on a Veriti 96-
well Thermal Cycler (Applied Biosystems) or Biometra Trio (Analytik Jena)
according to the manufacturer’s instructions. Speciﬁc PCR conditions are available
upon request.
Primers used to verify gene targeting events are described in Figs. 2 and 4 and
Supplementary Figs. 10 and 11, and Supplementary Table 7 and 8. Sequencing of
the junction regions was used to ensure the ﬁdelity of the ﬂanking µH and CRISPR-
Cas9 protospacers. PCR products from cassette-excised iPSC clones were
sequenced directly, while PCR products from populations were cloned using the
Zero Blunt TOPO PCR Cloning Kit for Sequencing (Invitrogen), and then
ampliﬁed and sequenced from the resulting bacterial colonies with Ex Taq DNA
Polymerase (Takara) and T3/T7 primers. Primer design for exons 1–9 of HPRT1
(Accession NG_012329.1) and exons 1-5 of APRT (Accession NG_008013.1) was
performed using the NCBI Primer-BLAST with optional settings for human repeat
ﬁlter, SNP handling, and primer pair speciﬁcity checking to H.sapiens (taxid:9606)
reference genome, and are listed in Supplementary Table 9.
Sequencing. PCR products were treated with ExoSAP-IT (Affymetrix) prior to
sequencing. DNA sequencing was performed using BigDye Terminator v3.1 Cycle
Sequencing Kit (Applied Biosystems), puriﬁcation by ethanol precipitation, and
run on a 3130xl Genetic Analyzer (Applied Biosystems). Sequence alignments were
performed using Sequencher v5.1 (Genecodes) or Snapgene v3.1.4 or higher (GSL
Biotech LLC.). Sequence trace ﬁles with poor base calling conﬁdence were excluded
from further analyses.
TIDE analysis. TIDE analysis of mixed sequences was performed using the online
tool at https://tide.nki.nl/20, or as a stand-alone R Script. Sequence data from H1
ESCs or 1383D6 iPSCs was used as a reference. For HPRT1 indels, populations of
ESCs or iPSCs consisting of ~50 clones (H1) or 200 clones (1383D6) were pooled
and harvested for genomic DNA and ampliﬁed as described above. As TIDE is
designed for CRISPR-Cas9, whereas TALENs induce DSBs at an undetermined
position within the spacer, we positioned the predicted breakpoint at the 5′ end of
the spacer adjacent the HPRT1_B TALEN-L binding site (TTCCTATGACTG-
TAGAT^TTT) where base-calling conﬁdence initially dropped co-incident with
visibly mixed sequence. The deletion size window was extended to 20 bp to
accommodate larger deletions. For resolving heterozygous APRT clones, the APRT
sgRNA-2 sequence was used to set the breakpoint and the deletion window was
extended to 50 bp in order to accommodate predicted NHEJ events. The remaining
parameters were set to default or allowed to adjust automatically based on the
properties of the sequence trace ﬁles provided.
RFLP analyses. In order to verify deposition of Silent mutations following excision
with unilaterally or bilaterally mutant µH, genomic DNA was ampliﬁed using
primer set dna1720/411 (HPRT1) or dna1711/1712 (APRT). Cleaved amplicons
were resolved by gel electrophoresis following treatment with or without AﬂII
(HPRT1) or Acc65I (APRT) restriction enzyme (Fermentas).
Southern blotting. The HPRT-B and APRT-5′ genomic, and mCherry transgenic
probe fragments were prepared from genomic or plasmid PCR amplicons,
respectively (Supplementary Table 10). DIG labeled dUTP (Roche) was incorpo-
rated by PCR ampliﬁcation using Ex Taq (Takara) according to the manufacturer’s
instructions.
Genomic DNA (5–10 µg) was digested with 3-fold to 5-fold excess restriction
endonuclease (Fermentas) overnight in the presence of BSA (100 µg/mL), RNaseA
(100 µg/mL) and spermidine (1 mM). Digested DNA fragments were separated on
a 0.8% agarose gel, depurinated, denatured, and transferred to a Hybond N + nylon
membrane (GE Healthcare) using 20 × SSC. The membrane was UV crosslinked,
pre-hybridized, and incubated with 150 ng digoxigenin (DIG)-labeled DNA probe
in 4 mL DIG Easy Hyb buffer (Roche) at 42 °C overnight with constant rotation.
After repeated washing at 65 °C (0.5 × SSC; 0.1% SDS), the membrane was blocked
(DIG Wash and Block Buffer Set, Roche) and alkaline phosphatase-conjugated
anti-DIG antibody (1:10,000, Roche) was applied to a membrane. Signals were
raised by CDP-star (Roche) and detected by ImageQuant LAS 4000 imaging system
(GE Healthcare). Uncropped images for Southern blot data presented in Figs. 2 and
4 are shown in Supplementary Fig. 19.
Microscopy. Phase-contrast and ﬂuorescence images were acquired on a BZ-X710
(KEYENCE) using appropriate ﬁlters and exposure times.
Drug sensitivity assays. iPSC lines edited at the HPRT1 locus and controls were
plated at 3 × 104 cells per well in a 6-well culture dish, grown for 2 days without
HAT, followed by 2 additional days with or without HAT. Cells were harvested on
days 2, 3, and 4 post-plating, and re-suspended in 100 µL of AK02N. An 11 μL
aliquot of cell suspension was mixed 1:1 with Trypan Blue Stain 0.4% (Gibco) by
gentle pipetting, and 10 μL was applied to each side of a Counting Slide (Bio-Rad).
Cell numbers were determined with the TC20 Automated Cell Counter (Bio-Rad).
iPSC lines edited at the APRT locus and controls were plated at 1 × 105 cells per
well in a 6-well culture dish in media containing Y-27632 and grown for 2 days. 2,
6-diaminopurine (DAP; Sigma) dissolved in DMSO was added to growth media at
a ﬁnal concentration of 10 µg/mL for an additional 2 days, after which the wells
were stained with crystal violet and imaged. Treatment with DMSO was used as a
control.
Crystal violet staining. Conﬂuent or drug-selected iPSC culture dishes were
washed twice with ice-cold DPBS and ﬁxed by ice-cold methanol (Nacalai Tesque)
for 10 min at room temperature. The methanol was removed and sufﬁcient crystal
violet solution (HT90132, Sigma-Aldrich) was added to cover the bottom of the
dish. After 10 min incubation at room temperature, the staining solution was
removed and the dishes were gently rinsed with water. After complete drying at
room temperature, whole well images were acquired with a STYLUS XZ-2
(OLYMPUS) camera.
Western blotting. For HPRT protein analysis, total cell lysates were prepared by
heating 1 × 106 cells to 70 oC for 10 min in 100 µL NuPAGE LDS Sample Buffer
(1×) (Thermo Fisher Scientiﬁc) containing DTT at a ﬁnal concentration of 50 mM.
Lysates were resolved on Bis-Tris gels, and probed using HPRT (F-1, sc-376938,
1:200, Santa Cruz) and anti-actin (A2066, 1:5,000, Sigma Aldrich) antibodies.
Sheep anti-Mouse IgG, HRP-Linked Whole Ab (GE Life Science:NA931-100UL)
and goat anti-rabbit IgG-HRP (Santa Cruz: sc-2004) secondary antibodies for
HPRT and anti-actin, respectively, were used at 1:5000 dilution. Signals were raised
using ECL Prime Western Blotting Detection Reagent (GE Healthcare) and
detected on an ImageQuant LAS 4000 imaging system (GE Healthcare).
Metabolome analysis. The concentrations of all the charged metabolites in media
samples were measured by capillary electrophoresis time-of-ﬂight mass spectro-
metry (CE-TOFMS, Agilent Technologies, Santa Clara, CA) using the methods
developed by the authors29,30. For media sample preparation, 1.5 × 105 cells from
the indicated iPSC clones were seeded in 150 µL of AK02N medium containing Y-
27632 (10 µM) per well of a 96-well plate and cultured at 37 °C, 5% CO2. The next
day, the medium was replaced with 150 µL of fresh AK02N medium without Y-
27632. Media-only reference samples were prepared and similarly incubated at 37 °
C, 5% CO2. After 24 h, 100 µL of spent medium was collected and mixed with 400
μL of methanol containing L-methionine sulfone (Wako), MES (Dojindo), and
CSA (Wako) internal standards (200 μM each). Following the addition of 200 μL
Milli-Q ultrapure water, the samples were extracted with 500 μL chloroform. The
aqueous layer was subjected to 5 kDa ultraﬁltration (HMT) and lyophilized
(LABCONCO). Lyophilized samples were resuspended in 50 μL Milli-Q ultrapure
water containing 3-Aminopyrrolidine (Sigma-Aldrich) and Trimesate (Wako)
internal standards (200 μM each) before analysis.
To analyze cationic compounds, a fused silica capillary (50 μm i.d. × 98 cm) was
used with 1 M formic acid as the electrolyte62. Methanol / water (50% v/v)
containing 0.01 μM hexakis (2,2-diﬂuoroethoxy) phosphazene was delivered as the
sheath liquid at 10 μl/min. ESI-TOFMS was performed in positive ion mode, and
the capillary voltage was set at 4 kV. Automatic recalibration of each acquired
spectrum was achieved using the masses of the reference standards ([13C isotopic
ion of a protonated methanol dimer (2MeOH+H)]+, m/z 66.0631) and ([hexakis
(2,2-diﬂuoroethoxy) phosphazene+H]+, m/z 622.0290). To identify metabolites,
relative migration times of all peaks were calculated by normalization to the
reference compound, 3-aminopyrrolidine. The metabolites were identiﬁed by
comparing their m/z values and relative migration times to the metabolite
standards. Quantiﬁcation was performed by comparing their peak areas to
calibration curves generated using internal standardization techniques with
methionine sulfone. The other conditions were identical to those described
previously29.
To analyze anionic metabolites, a commercially available COSMO(+)
(chemically coated with cationic polymer) capillary (50 μm i.d. × 105 cm) (Nacalai
Tesque, Kyoto, Japan) was used with a 50 mM ammonium acetate solution (pH
8.5) as the electrolyte. Methanol/5 mM ammonium acetate (50% v/v) containing
0.01 μM hexakis (2,2-diﬂuoroethoxy) phosphazene was delivered as the sheath
liquid at 10 μL/min. ESI-TOFMS was performed in negative ion mode, and the
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capillary voltage was set at 3.5 kV. For anion analysis, trimesate and D-Camphor-
10-sulfonic acid (CAS) were used as the reference and the internal standards,
respectively. The other conditions were identical to those described previously30.
The data were analyzed and quantiﬁed using in-house software (Master Hands-
2.17.1.11) developed particularly for CE-TOFMS-based metabolomic data analysis.
Data availability. Previously published data used in primer design for exons 1-9 of
HPRT1 and exons 1-5 of APRT are available from NCBI Genbank under accession
codes NG_012329.1 and NG_008013.1, respectively.
Plasmids used in this study are available through Addgene (107271 - 107281) or
upon request. Complete CE-TOFMS metabolomics data and DNA sequence
alignments are available upon request. All other data are available upon request.
Received: 23 December 2017 Accepted: 16 January 2018
References
1. Kim, H. & Kim, J. S. A guide to genome engineering with programmable
nucleases. Nat. Rev. Genet. 15, 321–334 (2014).
2. Sakuma, T. & Woltjen, K. Nuclease-mediated genome editing: at the front-line
of functional genomics technology. Dev. Growth Differ. 56, 2–13 (2014).
3. Hockemeyer, D. & Jaenisch, R. Induced pluripotent stem cells meet genome
editing. Cell. Stem. Cell 18, 573–586 (2016).
4. Capecchi, M. R. Gene targeting in mice: functional analysis of the mammalian
genome for the twenty-ﬁrst century. Nat. Rev. Genet. 6, 507–512 (2005).
5. Davis, R. P. et al. A protocol for removal of antibiotic resistance cassettes from
human embryonic stem cells genetically modiﬁed by homologous
recombination or transgenesis. Nat. Protoc. 3, 1550–1558 (2008).
6. Firth, A. L. et al. Functional gene correction for cystic ﬁbrosis in lung epithelial
cells generated from patient iPSCs. Cell Rep. 12, 1385–1390 (2015).
7. Meier, I. D. et al. Short DNA sequences inserted for gene targeting can
accidentally interfere with off-target gene expression. FASEB J. 24, 1714–1724
(2010).
8. Ye, L. et al. Seamless modiﬁcation of wild-type induced pluripotent stem cells
to the natural CCR5Delta32 mutation confers resistance to HIV infection.
Proc. Natl Acad. Sci. USA 111, 9591–9596 (2014).
9. McVey, M. & Lee, S. E. MMEJ repair of double-strand breaks (director’s cut):
deleted sequences and alternative endings. Trends Genet. 24, 529–538 (2008).
10. Merkle, F. T. & Eggan, K. Modeling human disease with pluripotent stem
cells: from genome association to function. Cell. Stem. Cell. 12, 656–668
(2013).
11. Wilson, J. M., Baugher, B. W., Landa, L. & Kelley, W. N. Human
hypoxanthine-guanine phosphoribosyltransferase. Puriﬁcation and
characterization of mutant forms of the enzyme. J. Biol. Chem. 256,
10306–10312 (1981).
12. Kamatani, N. et al. Identiﬁcation of a compound heterozygote for adenine
phosphoribosyltransferase deﬁciency (APRT*J/APART*Q0) leading to 2,8-
dihydroxyadenine urolithiasis. Hum. Genet. 85, 500–504 (1990).
13. Sakuma, T. et al. Efﬁcient TALEN construction and evaluation methods for
human cell and animal applications. Genes. Cells 18, 315–326 (2013).
14. Cermak, T. et al. Efﬁcient design and assembly of custom TALEN and other
TAL effector-based constructs for DNA targeting. Nucleic Acids Res. 39, e82
(2011).
15. Bae, S., Kweon, J., Kim, H. S. & Kim, J. S. Microhomology-based choice of
Cas9 nuclease target sites. Nat. Methods 11, 705–706 (2014).
16. Oceguera-Yanez, F. et al. Engineering the AAVS1 locus for consistent and
scalable transgene expression in human iPSCs and their differentiated
derivatives. Methods 101, 43–55 (2016).
17. Thomson, J. A. et al. Embryonic stem cell lines derived from human
blastocysts. Science 282, 1145–1147 (1998).
18. Sakuma, T. et al. Repeating pattern of non-RVD variations in DNA-binding
modules enhances TALEN activity. Sci. Rep. 3, 3379 (2013).
19. Ochiai, H. et al. Targeted mutagenesis in the sea urchin embryo using zinc-
ﬁnger nucleases. Genes. Cells 15, 875–885 (2010).
20. Brinkman, E. K., Chen, T., Amendola, M. & van Steensel, B. Easy quantitative
assessment of genome editing by sequence trace decomposition. Nucleic Acids
Res. 42, e168 (2014).
21. Woltjen, K., Oceguera-Yanez, F., Kagawa, H. & Kim, S.-I. in Genome Editing.
(ed. Turksen, K.) 45–64 (Springer, Cham, 2016).
22. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat.
Protoc. 8, 2281–2308 (2013).
23. Jinek, M. et al. A programmable dual-RNA-guided DNA endonuclease in
adaptive bacterial immunity. Science 337, 816–821 (2012).
24. Fu, Y. et al. High-frequency off-target mutagenesis induced by CRISPR-Cas
nucleases in human cells. Nat. Biotechnol. 31, 822–826 (2013).
25. Doench, J. G. et al. Optimized sgRNA design to maximize activity and minimize
off-target effects of CRISPR-Cas9. Nat. Biotechnol. 34, 184–191 (2016).
26. Cariello, N. F., Scott, J. K., Kat, A. G., Thilly, W. G. & Keohavong, P.
Resolution of a missense mutant in human genomic DNA by denaturing
gradient gel electrophoresis and direct sequencing using in vitro DNA
ampliﬁcation: HPRT Munich. Am. J. Hum. Genet. 42, 726–734 (1988).
27. Wilson, J. M. & Kelley, W. N. Human hypoxanthine-guanine
phosphoribosyltransferase. Structural alteration in a dysfunctional enzyme
variant (HPRTMunich) isolated from a patient with gout. J. Biol. Chem. 259,
27–30 (1984).
28. Wilson, J. M., Baugher, B. W., Mattes, P. M., Daddona, P. E. & Kelley, W. N.
Human hypoxanthine-guanine phosphoribosyltransferase. Demonstration of
structural variants in lymphoblastoid cells derived from patients with a
deﬁciency of the enzyme. J. Clin. Invest 69, 706–715 (1982).
29. Soga, T. et al. Differential metabolomics reveals ophthalmic acid as an
oxidative stress biomarker indicating hepatic glutathione consumption. J. Biol.
Chem. 281, 16768–16776 (2006).
30. Soga, T. et al. Metabolomic proﬁling of anionic metabolites by capillary
electrophoresis mass spectrometry. Anal. Chem. 81, 6165–6174 (2009).
31. Grzesiuk, E. & Carroll, D. Recombination of DNAs in Xenopus oocytes based
on short homologous overlaps. Nucleic Acids Res. 15, 971–985 (1987).
32. Decottignies, A. Microhomology-mediated end joining in ﬁssion yeast is
repressed by pku70 and relies on genes involved in homologous
recombination. Genetics 176, 1403–1415 (2007).
33. Elliott, B., Richardson, C., Winderbaum, J., Nickoloff, J. A. & Jasin, M. Gene
conversion tracts from double-strand break repair in mammalian cells. Mol.
Cell. Biol. 18, 93–101 (1998).
34. Hatada, S. et al. Isolating gene-corrected stem cells without drug selection.
Proc. Natl Acad. Sci. USA 102, 16357–16361 (2005).
35. Turker, M. S. & Martin, G. M. Induction of adenine salvage in mouse cell lines
deﬁcient in adenine phosphoribosyltransferase. Mol. Cell. Biol. 5, 2662–2668
(1985).
36. Smithies, O., Gregg, R. G., Boggs, S. S., Koralewski, M. A. & Kucherlapati, R. S.
Insertion of DNA sequences into the human chromosomal beta-globin locus
by homologous recombination. Nature 317, 230–234 (1985).
37. Thomas, K. R. & Capecchi, M. R. Site-directed mutagenesis by gene targeting
in mouse embryo-derived stem cells. Cell 51, 503–512 (1987).
38. Yang, L. et al. Optimization of scarless human stem cell genome editing.
Nucleic Acids Res. 41, 9049–9061 (2013).
39. Orlando, S. J. et al. Zinc-ﬁnger nuclease-driven targeted integration into
mammalian genomes using donors with limited chromosomal homology.
Nucleic Acids Res. 38, e152 (2010).
40. Maresca, M., Lin, V. G., Guo, N. & Yang, Y. Obligate ligation-gated
recombination (ObLiGaRe): custom-designed nuclease-mediated targeted
integration through nonhomologous end joining. Genome Res. 23, 539–546
(2013).
41. Nakade, S. et al. Microhomology-mediated end-joining-dependent integration
of donor DNA in cells and animals using TALENs and CRISPR/Cas9. Nat.
Commun. 5, 5560 (2014).
42. Grindley, N. D., Whiteson, K. L. & Rice, P. A. Mechanisms of site-speciﬁc
recombination. Annu. Rev. Biochem. 75, 567–605 (2006).
43. Villarreal, D. D. et al. Microhomology directs diverse DNA break repair
pathways and chromosomal translocations. PLoS Genet. 8, e1003026 (2012).
44. Liu, Z. et al. Efﬁcient CRISPR/Cas9-mediated versatile, predictable, and
donor-free gene knockout in human pluripotent stem cells. Stem Cell Rep. 7,
496–507 (2016).
45. Daley, J. M. & Wilson, T. E. Rejoining of DNA double-strand breaks as a
function of overhang length. Mol. Cell. Biol. 25, 896–906 (2005).
46. Glover, L., Jun, J. & Horn, D. Microhomology-mediated deletion and gene
conversion in African trypanosomes. Nucleic Acids Res. 39, 1372–1380 (2011).
47. Truong, L. N. et al. Microhomology-mediated end joining and homologous
recombination share the initial end resection step to repair DNA double-
strand breaks in mammalian cells. Proc. Natl Acad. Sci. USA 110, 7720–7725
(2013).
48. Paquet, D. et al. Efﬁcient introduction of speciﬁc homozygous and
heterozygous mutations using CRISPR/Cas9. Nature 533, 125–129 (2016).
49. Erard, N., Knott, S. R. V. & Hannon, G. J. A CRISPR resource for individual,
combinatorial, or multiplexed gene knockout. Mol. Cell. 67, 348–354 (2017).
50. Chen, J. S. et al. Enhanced proofreading governs CRISPR-Cas9 targeting
accuracy. Nature 550, 407–410 (2017).
51. Yusa, K. et al. Targeted gene correction of alpha1-antitrypsin deﬁciency in
induced pluripotent stem cells. Nature 478, 391–394 (2011).
52. Woltjen, K. et al. piggyBac transposition reprograms ﬁbroblasts to induced
pluripotent stem cells. Nature 458, 766–770 (2009).
53. Osafune, K. et al. Marked differences in differentiation propensity among
human embryonic stem cell lines. Nat. Biotechnol. 26, 313–315 (2008).
54. Kyttala, A. et al. Genetic variability overrides the impact of parental cell type
and determines iPSC differentiation potential. Stem Cell Rep. 6, 200–212 (2016).
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03044-y ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:939 |DOI: 10.1038/s41467-018-03044-y |www.nature.com/naturecommunications 13
55. Takahashi, K. et al. Induction of pluripotent stem cells from adult human
ﬁbroblasts by deﬁned factors. Cell 131, 861–872 (2007).
56. Chen, Y. T. & Bradley, A. A new positive/negative selectable marker,
puDeltatk, for use in embryonic stem cells. Genesis 28, 31–35 (2000).
57. Reyon, D. et al. FLASH assembly of TALENs for high-throughput genome
editing. Nat. Biotechnol. 30, 460–465 (2012).
58. Kim, S. I. et al. Inducible transgene expression in human iPS cells using
versatile all-in-one piggyBac transposons. Methods Mol. Biol. 1357, 111–131
(2016).
59. Okita, K., Hong, H., Takahashi, K. & Yamanaka, S. Generation of mouse-
induced pluripotent stem c ells with plasmid vectors. Nat. Protoc. 5, 418–428
(2010).
60. Okita, K. et al. A more efﬁcient method to generate integration-free human
iPS cells. Nat. Methods 8, 409–412 (2011).
61. Ramirez-Solis, R. et al. Genomic DNA microextraction: a method to screen
numerous samples. Anal. Biochem. 201, 331–335 (1992).
62. Soga, T. & Heiger, D. N. Amino acid analysis by capillary electrophoresis
electrospray ionization mass spectrometry. Anal. Chem. 72, 1236–1241 (2000).
Acknowledgements
We would like to acknowledge the technical assistance of Kikumi Horiguchi for initial
TALEN evaluation and genotyping, Chiho Sakurai for cell culture support, and Kanae
Mitsunaga for FACS. Norikazu Saiki and Megumu Saito provided advice in setting up
iPSC metabolomics. We thank Koichi Kawakami for provision of the CAG promoter, as
well as Rudolf Jaenisch, Daniel Voytas, and Feng Zhang for provision of reagents through
Addgene. This work was funded in part by grants to K.W. from the Japan Society for the
Promotion of Science (Wakate B), the Kyoto University Hakubi Project, and the
Research Center Network for Realization of Regenerative Medicine, Program for
Intractable Diseases Research Utilizing Disease-Speciﬁc iPS Cells, of the Japan Agency
for Medical Research and Development (AMED). K.W. is a Hakubi Center Special
Project Researcher.
Author contributions
K.W. conceived the study. S.-I.K. and T.M. performed the majority of experiments. H.K.
performed TA cloning and WB analysis. R.H. constructed plasmids and M.N. performed
PCR genotyping. T.S. and T.Y. assembled HPRT Avr-TALENs. A.U., M.O. and T.So.
performed CE-MS analysis. S.-I.K., T.M., H.K. and K.W. interpreted data and K.W. wrote
the manuscript with feedback from all authors. All authors approved the ﬁnal
manuscript.
Additional information
Supplementary Information accompanies this paper at https://doi.org/10.1038/s41467-
018-03044-y.
Competing interests: S.-I.K., T.M. and K.W. are inventors on a patent applied for by
Kyoto University covering the research reported herein (PCT/IB2017/054736). The
remaining authors declare no competing ﬁnancial interests.
Reprints and permission information is available online at http://npg.nature.com/
reprintsandpermissions/
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional afﬁliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2018
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03044-y
14 NATURE COMMUNICATIONS |  (2018) 9:939 |DOI: 10.1038/s41467-018-03044-y |www.nature.com/naturecommunications
